The 7-globin genes from a patient homozygous for a deletion form of hereditary persistence of fetal hemoglobin (HPFH-1) have been cloned and sequenced. The DNA sequence of the patient's 7-globin genes corresponds to a previously identified sequence framework (chromosome A) with the exception of 10 base changes. Seven of these base changes can be attributed to normal allelic variation generated by small gene conversion events. The remaining three base changes are present in a 0.76 kb Hindlll fragment containing a putative enhancer located 3' to the "7-globin gene. The same three base changes have also been described in the Seattle variant of nondeletion HPFH. We have analyzed 16 alleles from non-HPFH individuals and five alleles from individuals with nondeletion or deletion EREDITARY PERSISTENCE of fetal hemoglobin H (HPFH) is a benign condition in which fetal hemoglobin expression persists into adulthood at levels greater than 1% in the absence of erythropietic stress or thala~semia.'-~ Because this condition can be viewed as a failure to switch from fetal (HbF, a2y2) to adult (HbA, ad2) hemoglobin synthesis, it has been studied as a model for the developmental control of gene expression.
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Two major categories of HPFH have been delineated based on mutations associated with these disorders. Nondeletion HPFH is commonly associated with single base changes in the 5' flanking region of the y-globin genes. These mutations may alter promoter sequences or binding sites for trans-acting factors, resulting in a corresponding over expression of either the '7-globin or *y-globin gene.5-'2 Deletion HPFH is characterized by large (= 105 kb) deletions in the &globin gene cluster that remove the adult (6 and @) globin genes and result in increased expression of both Gy-and *y-gl~bin.'~-' ' One hypothesis to explain the increase in y-globin gene expression in the deletion form of HPFH described in American blacks (HPFH-1) is that the sequences juxtaposed to the y-globin genes as a result of the deletion contain an enhancer-like element that serves to maintain a transcriptionally active domain. A small fragment of DNA from the region immediately 3' to the breakpoint in HPFH-1 has been found to have enhancer-like activity when transfected into erythroid cells.20.2' This region of DNA is also hypomethylated and DNAse I hypersensitive in erythroid tissues and contains a large open-reading frame (ref 20-22; Elder and Groudine, personal communication, March, 1989) . Furthermore, deletions that extend beyond the enhancer-like element result in SPo thalassemia instead of HPFH.2'323 However, no single model has been proposed that successfully explains the mechanism underlying all forms of deletion HPFH. 24 The sequences of the y-globin genes from patients with deletion HPFH have never been directly examined for mutations analogous to those present in nondeletion HPFH. Such mutations might provide an additional explanation for the persistence in expression of the y-globin genes in deletion HPFH. We have cloned and sequenced the y-globin genes HPFH for the presence of these base changes by polymerase chain reaction amplification of cloned or chromosomal DNA and hybridization to allele-specific oligonucleotide probes. Although these base changes were found in an individual with HPFH-2, they were not found in the DNA from two patients with nondeletion HPFH. More importantly, all three base changes were detected in DNA from five non-HPFH individuals and appear to be common in blacks. We conclude that these base changes do not correlate with an HPFH phenotype and that the significant mutation in HPFH-1 is the deletion of over 100 kb of genomic DNA. 0 1990 by The American Society of Hematology.
from a patient homozygous for HPFH-1. Of the 10 base changes identified, 7 correspond to known sequence polymorphisms, and 3 base changes located in the *y gene 3' enhancer" have been described previously in the Seattle variant of nondeletion HPFH.26 Further analysis of DNA from non-HPFH individuals indicates that these three base changes are present in normal y-globin gene sequences and are unlikely to contribute to the increase in y-globin gene expression observed in HPFH-1.
METHODS

Genomic
DNA from a lymphoblastoid cell line, LAZ-149;' obtained from a black patient homozygous for HPFH-1,I5 was digested to completion with BglII (New England Biolabs, Beverly, MA). EMBL 3 phage arms (Promega Biotec, Madison, WI) were prepared by digestion of the vector with BamHl and EcoR1, followed by precipitation with isopropanol, as described in the manufacturer's protocol. Phage arms and digested genomic DNA were ligated in a 10 pL reaction containing 66 mmol/L Tris-HC1 (pH 7.5), 5 mmol/L MgCl,, 5 mmol/L DTT, 1 mmol/L adenosine triphosphate (ATP), and 3 units of T4 DNA ligase (Pharmacia, Piscataway, NJ). Ligation reactions were incubated at 16OC for 16 hours. A portion of the ligation mixture was then packaged using Gigapack packaging extracts (Stratagene, San Diego, CA) according to the manufacturer's 500 STOLLE ET AL suggestions. VCS 257 bacteria were infected with the packaged phage DNA and plated using standard methods." Approximately lo5 recombinant phage plaques were screened by hybridization with a nick translated 2.6 kb EcoRI fragment from the 5' end of the Ay-globin gene. Potential positive clones were counter screened with a 1.6 kb EcoRI fragment from the 3' end of the Gy-globin gene. Positive identification was achieved by restriction enzyme digestion, and Southern blot analysis of insert DNA was compared with a 13 kb BglII fragment of normal DNA containing the Gy-and *y-globin genes.
Insert DNA containing the y-globin genes from one of the patient's chromosomes was excised from the vector by digestion with SalI. A Gy-globin fragment (2.6 kb StuIISphI) digested with AluI and an Ay-globin fragment (2.2 kb RsaI) digested with HaeIII were blunt end ligated into M13mpl0, which had been linearized with SmaI. In addition, a 0.76 kb Hind111 fragment from the region 3' to the patient's Ay-globin gene was similarly subcloned. Single stranded or double stranded M13 templates were sequenced using the dideoxy sequencing method and Sequenase (US Biochemicals, Cleveland, Each fragment was sequenced at least twice using several independent isolates of M13 subclones (Fig 1) .
Amplification of genomic DNA and hybridization with allelespecijc oligonucleotide probes. Genomic DNA (1 p g ) was amplified by the polymerase chain reaction technique for 30 cycles with 1.5 minute denaturations at 94OC, primer annealing for 2 minutes at 5S0C, and extensions for 3 minutes at 720C3' Amplified DNA (1% to 2% of reaction product) was denatured in a solution of 0.4 N St" I L.-.
GY AY
NaOH and 25 mmol/L EDTA and blotted onto a Nytran membrane (Schleicher and Schuell, Keene, NH) using a slot blot manifold. Oligonucleotide probes corresponding to the *y-globin gene published sequence (TTGGAAGGT TTACTTAA; AGGTTTAGC T-GAGCTCA; AGCACCTTACACTGAGT)32.33 or the Seattle variant (TTGGAAGGCTTACTTAA; AGGTTTAGATGAGCTCA; AGCACCTTGCACTGAGT)26 were 5' end-labelled to a specific activity of 1 x lo7 cpmlpg using T4 polynucleotide kinase (Boehringer, Mannheim, W Germany) and y-[32P]dATP (Amersham, Chicago, IL). Each probe was hybridized to the membrane-bound amplified DNA at 5OC below its calculated melting temperature. The membrane was then washed at 2OC below the probe melting temperature to remove nonspecifically bound probe. 34 The filters were exposed to X-ray film (Kodak, Rochester, NY) at -7OOC with an intensifying screen.
RESULTS
The LAZ-149 cells used in this study were derived from a patient who was the subject of previous report^.'^^'"^*^ The patient is homozygous for a form of HPFH common among American blacks (HPFH-1) as determined by Southern blot analy~is.'~-'~ The two y-globin gene loci were indistinguishable by restriction enzyme mapping and presumed to contribute identically to the HPFH phenotype. The '7-and *yglobin genes from one of the patient's two chromosomes Table 1 . The position of each base change is relative to the cap site for the "7-*Base changes not identified in normal y-globin gene sequence.
or Ay-globin genes, respectively.
bearing the deletion form of HPFH-1 were sequenced (Fig 1) and compared with the sequence of previously reported '7- and Ay-globin The sequence of the '7-globin gene from -383 to +2,209 bp (relative to the cap site) was identical to 'y-globin from the previously reported chromosome A sequence f r a m e~o r k , '~ except for a deletion of one of eight T's (+ 1,611 to + 1,618) and a CG-T substitution (+ 1,800 and + 1,801; Fig 1B and Table 1 ). Both of these nucleotide base changes are present in the normal '7-globin gene of the B chromosome framework (Slightom, personal communication, February 1988) and, as such, are not likely to be responsible for the increase in expression of both '7- and Ay-globin genes characteristic of this condition. A T at -158 (which creates a restriction enzyme cleavage site for XmnI) is normal for a 'y-globin gene from chromosome A and is present in the patient's DNA sequence. The presence of a T a t -158 has been associated with a 'yAy ratio of 60:40 in nonanemic adults and a small increase in HbF (of the Gy variety) in patients with sickle cell anemia or B thala~semia,~' but cannot explain the large increase in both '7- and Ay-globin observed in this patient. The presence of a T at -158 of the ' y gene has also been demonstrated in other individuals with HPFH-1 . 36 The sequence of the Ay-globin gene from -383 bp to + 1,760 bp (relative to the cap site) was also identical to the published sequence for a chromosome A y-globin gene, except for a single base change (C-G) at position -369 (Fig 1C and Table 1) . A G a t position -369 is characteristic of a normal Ay-globin gene from chromosome B33 and is therefore not a candidate for the mutation underlying HPFH. To obtain sequences from the area further 5' of the Ay-globin gene, a 5.0 kb StuI fragment containing the 'y-globin gene and the 'yAy inter-genic region derived from the patient's cloned DNA was subcloned into M13 and sequenced as described above using a universal primer. Three additional base changes were detected: a deletion of one A in a string of four at -601 to -603; an insertion of an A at -605; and a deletion of a T at -61 1 (Fig 1C and Table 1 ).
The three base changes support the notion that a gene conversion event has occurred in which the 5' end of the Ay(A) gene has been converted to an Ay(B) gene. However, the predicted base change at position -588 (A-G), which would have been consistent with a gene conversion event involving the entire sequence from -369 to -61 1, was not observed.
Small regions of converted gene sequence interspaced by nonconverted regions have been identified previously in the y-globin genes and have been called "patchy" gene conversion~.~'.~* Such gene conversions are relatively common in y-globin gene sequences and frequently result in an Ay-globin gene converted to a 'y-globin gene sequence. The base changes described here clearly suggest conversion of an Ay (A)-type chromosome to an Ay (B)-type sequence, and not conversion by a 'y-globin gene (Fig 2) . In any event, the conversion of the sequences of a normal y-globin gene to that of another normal y-globin gene cannot explain the phenotype of y-globin gene expression in this patient.
Since no base changes similar to the mutations that give rise to nondeletion HPFH were detected, the sequence of the putative enhancer located 3' to the Ay-globin gene was examined. A 0.76 kb HindIII fragment from the 3' end of the Ay-globin gene (Fig 1) was isolated from a digest of the 13 kb Sal1 HPFH-1 fragment by gel electrophoresis and electroelution. The HindIII ends were filled using a mixture of all four dNTPs and the large fragment of DNA polymerase. The fragment was then blunt end ligated into M13mplO and DNA templates were sequenced as described above. Four sequence differences were detected:( 1) T-C at +2,276; (2) GG-AA a t +2,357 and +2358; (3) C-A at +2,451; and (4) A-G a t +2,667 relative to the Ay-globin gene cap site ( Fig 1C and Table 1 ). One of these changes (GG-AA) is characteristic of a normal Ay-globin gene of the B chromo-
Ay (B)
Gy ( some framework. The remaining three base changes have been identified in a variant of nondeletion HPFH in Seattle. 26 To determine whether these three base changes represent mutations that underlie HPFH, cloned or genomic DNAs from patients with deletion or nondeletion HPFH. other unrelated disorders (HbS, @ thalassemia and HbE), and without hemoglobinopathies were amplified using the polymerase chain reaction, applied to a nylon membrane, and hybridized to allele-specific oligonucleotide probes. Representative results for the sequence variation found at position +2,667 are shown in Fig 3. The results of this analysis (Table 2) indicate that the three base changes are ( I ) usually inherited as a cluster; (2) not found in two nondeletion HPFH alleles; (3) present in a patient homozygous for another major form of deletion HPFH (HPFH-2); but (4) also present in patients with hemoglobinopathies unrelated to HPFH (ie, HbS) as well as in four individuals without hemoglobinopathies, all of whom had normal HbF levels. Interestingly, sequences corresponding to the Seattle variant were detected in the genomic DNA from 9 of 1 I black individuals, suggesting that these sequences may represent a cluster of polymorphisms common among blacks. However, the presence of the variant sequence in individuals with normal HbF levels indicates that these base changes alone are insufficient to increase Gy-and *y-globin levels and are not likely to contribute to the phenotype of HPFH.
DISCUSSION
The phenotypic expression of HPFH is variable.'" The distribution of HbF may be heterocellular or pancellular in erythrocytes. The composition of HbF may reflect an increase in predominantly Gy-globin, 'y-globin, or both. The increase in HbF may be associated with large deletions in the @-globin gene cluster, point mutations in the promoter regions of the Gy-or '?-globin genes.' or as yet undefined mutations either linked to the @-globin gene cluster or at some distant locu~.~~~"O A common form of HPFH in American blacks (HPFH-I) is associated with a deletion of approximately 105 kb in the @-globin gene cluster, which removes the 6-and @-globin genes and extends over 80 kb 3' to the @-globin gene."." HPFH-I is characterized by an increase in both Gy-and "7- globin expression (Gy, 50.7% f 4.3%)," an HbF level of approximately 30% in heterozygotes, and pancellular distribution. Feingold and Forget" have identified an enhancerlike sequence in the region 3' to the deletion breakpoint in HPFH-I, which is brought to within 8 to 10 kb of the y-globin genes as a result of the deletion. The enhancer-like region increased the activity of a linked CAT gene when plasmid constructs were transfected into K562 cells. The DNA from this region was also hypomethylated and DNase I hypersensitive only in erythroid tissues and contained a large open reading frame. The enhancer-like region may serve to maintain the y-globin genes in a transcriptionally active configuration, and, as a result, contribute to the phenotype of HPFH. However, it is also possible that as yet undetected mutations linked to the @-globin gene cluster or at some distant locus may be responsible (in part or in whole) for the increase in y-globin gene expression in HPFH-1. Unlike the mutations identified in nondeletion HPFH, such a mutation(s) would have to account for the increase in both 'y-and Ay-globin gene expression observed in the deletion form of HPFH. We have examined the sequence of the '7-and Ay-globin genes from a patient homozygous for HPFH-I for mutations that might contribute to the phenotype.
The '7- and Ay-globin genes from an HPFH-1 patient revealed a total of 10 sequence differences compared with published sequences.',32333 Two of these base changes are located within 230 bp of the '7-globin gene poly A signal, and both are present in normal allelic variants of 'y-globin. Four base changes are located 5' of the Ay-globin gene and appear to be vestiges of a "patchy" gene conversion event in which an Ay (A)-chromosome was converted to an *y (B)-type gene sequence. Four sequence differences were identified in the putative enhancer located 3' to the Ay-globin gene. One sequence change (G-AA)
is found in normal Ay-globin genes of a B chromosome framework (Fig 1 and Table 1 ). The remaining three base changes have also been reported by Gelinas et a126 in the 3' enhancer region in cis to the y-globin genes of a patient heterozygous for nondeletion HPFH (Seattle variant).
The presence of an identical cassette of base changes in both deletion and nondeletion forms of HPFH raised the possibility that one or all of these base changes may contribute to the increase in y-globin gene expression observed in these conditions. However, analysis of amplified genomic DNA from a variety of patients with normal or elevated H b F by hybridization to allele-specific oligonucleotide probes failed to detect a correlation between elevated y-globin gene expression and the presence of the three base changes. Furthermore, the presence of these base changes in patients unaffected by HPFH argues against a role for these base changes in increasing y-globin gene expression.
While this manuscript was in preparation, two other groups reported similar findings. Han et a142 sequenced the 3' Ay-globin gene enhancer from four individuals with various levels of HbF expression (including one patient with nondeletion HPFH) and found that the presence of the Seattle variant sequence did not necessarily correlate with high H b F levels. Bouhassira et a143 analyzed 196 chromosomes from normal individuals of various ethnic groups for the presence or absence of the variant sequence by polymerase amplification of the 3' Ay-globin gene region followed by allele-specific oligonucleotide hybridization or restriction enzyme digestion. They observed the three base changes in every ethnic group studied. In particular, the changes were present in 100% of native Africans homozygous for HbS, and 93% of American blacks with HbA. It is of interest to note that our black patient with ' y -202 nondeletion HPFH does not have these variant sequences. Thus, our data and that of other^^^,^^ suggest that these base changes are not causally related to HPFH, but instead represent clustered polymorphic sites common in the black population. Such a clustering of polymorphic sites has been described previously in the 5' flanking region of the &globin gene. 44 In summary, sequence analysis of the promoter regions of the '7- and Ay-globin genes and the 3' Ay-globin enhancer element from a patient with deletion HPFH failed to reveal a mutation(s) likely to increase both '7- and Ay-globin expression. It is possible that as yet unidentified mutations within the /3-globin gene cluster or at some distant site (such as in the gene for a trans-acting factor) contribute to the HPFH phenotype. However, in the absence of other detectable mutations that correlate with increased '7-and Ay-globin levels, we conclude that the significant mutation in HPFH-1 is the deletion of over 100 kb of genomic DNA.
